Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. - Wikidata - awgldk - TriplyDB

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

http://www.wikidata.org/entity/Q37096795

about

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations Integrated therapy for HIV and cryptococcosis In Vitro Activity of Isavuconazole against Rasamsonia Species Treatment considerations in pulmonary coccidioidomycosis.Intrathecal Amphotericin B: A 60-Year Experience in Treating Coccidioidal Meningitis.Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.Histoplasmosis in transplant recipients.Opportunistic Invasive Mycoses in AIDS: Cryptococcosis, Histoplasmosis, Coccidiodomycosis, and Talaromycosis.New pharmacological opportunities for the treatment of invasive mould diseases.Isavuconazole: is there a need for a new antifungal?Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.The war on cryptococcosis: A Review of the antifungal arsenal.Severe acute respiratory distress syndrome in a liver transplant patient.Present and Future Therapy of Infections

P2860

Q28067726-9DB9D56D-2155-46A7-8DF9-50EB06A80D7A Q28077707-C23F6C64-41D5-45E1-8C64-D6B2DAAF9C8E Q36104417-9727BEFB-124F-4FC4-BFDF-07D973BF106E Q38820536-08DBF1DA-7906-4D70-BF99-A9B607F33335 Q39032299-2508EBFC-EA7D-4A8F-BFC8-001856F40F83 Q39064815-DEC0C7E4-E17A-4F00-8CBA-7EA92638CA38 Q40043530-1F000B28-1248-4F32-BC98-CE74E4016291 Q40074359-04194863-4DDA-4CAE-AE34-2F69BAECEC2E Q40273481-618D73D1-7F0F-4B64-90B6-16E92BCE4D98 Q40273512-B2D17FD7-C6B3-40FB-A033-C527806DB3F2 Q41188300-D3F7C179-86AA-4831-A04E-1BEE7BB0826E Q47151374-69602F1D-1D0C-46F9-813A-A57BE92B1F45 Q47290283-D987D29F-B4CF-47F5-B0A3-C40077AFA965 Q47660181-546DDE2C-53E6-40E5-A450-080D4E28DA5A Q54214603-64744139-F325-40C5-90B6-59EFD43FE509 Q54260674-3EF7683D-988A-4495-8331-698A5B66A21E Q55426749-84E19BAC-CDF2-4C50-B43B-EC3C3D7D8A04 Q57177336-189073B2-A467-433D-9077-FDE893CA0373

P2860

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

http://www.wikidata.org/entity/Q37096795

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@en

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@nl

type

label

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@en

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@nl

prefLabel

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@en

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@nl

P1433

Q37096795-0AD65271-42F3-474C-9AF7-D46518DD1ED1

P1476

Q37096795-66ECEB8D-83AD-411C-AE9B-5A473F19D97D

P2093

Q37096795-05DEA7CF-82BA-4AA8-80D5-A391EC741224

Q37096795-0AA2FFAC-9BC4-41F0-96F5-B3F3E31F33C4

Q37096795-0D983C10-B055-43F5-A1F1-159081DDB185

Q37096795-2E8BBECE-87B8-433D-A400-584D59DAB184

Q37096795-3252C7FD-B639-4404-AB84-6E4923A96BE0

Q37096795-3F465B79-2277-4B08-B8DB-E7E2B0590FC9

Q37096795-6B2B95F3-3F6C-4B9C-92D1-AD55F7BC051A

Q37096795-75F346C0-F0ED-4A7F-B3C6-41781690189E

Q37096795-80A206E2-840E-44BA-AA1A-014414BF5363

Q37096795-A2BA8AAB-915A-4BF9-A411-00297230CA7F

P2860

Q37096795-01959391-1023-4BA8-A006-FDCCC78B13BB

Q37096795-0FE51E05-250D-4A54-A596-A4A9E2DC3767

Q37096795-1249BEE6-A4E3-47C7-B015-C12DCC9212E1

Q37096795-1285C924-7F41-4710-8B35-B519A1476B8F

Q37096795-1A0BD3CD-15C5-405F-836A-DB9E3F05C5E6

Q37096795-1C5A8B15-1998-4B10-8BF4-E4D7BA839AF0

Q37096795-242E1B63-758B-487B-808D-9EE37EC6DDD5

Q37096795-257287AA-2D18-4980-AF27-18B0FED7CB16

Q37096795-531738A5-FA0F-413A-9F1F-E8A68083DA40

Q37096795-555969D4-57D2-4932-BA2E-E2C60BCD6FE6

P304

Q37096795-C650A2E9-0593-4513-81DC-A7EFEF853FEE

P31

Q37096795-6ADC5D8B-635D-4FC3-85C0-BC97DEBE7D24

P356

Q37096795-73E28FAD-A57B-47A3-83F1-C962302D1FEB

P407

Q37096795-276C7B6C-BAA2-45C5-807D-A7EA66195B42

P433

Q37096795-0C12F60C-110E-421D-8503-270B90A8CD50

P478

Q37096795-7A7BA3E3-2822-47C0-A830-55F098116394

P50

Q37096795-8D6B5AF0-C81E-4024-A13B-C5CB04A55BFD

P577

Q37096795-9B616B70-BE3B-463C-B352-169C51C97611

P698

Q37096795-58BC13C9-D7F6-425E-9432-C87ACC042B4A

P921

Q37096795-F4B28C85-FBBE-4742-BB56-2E31DB190F7D

P932

Q37096795-4F71FDAE-80AB-453F-A0B2-C54A14E14596

P356

P1433

Clinical Infectious Diseases

P1476

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

@en

P2093

Adrian Rendon

http://www.w3.org/2001/XMLSchema#string

Flavio Queiroz-Telles

http://www.w3.org/2001/XMLSchema#string

George R Thompson

http://www.w3.org/2001/XMLSchema#string

Jose A Vazquez

http://www.w3.org/2001/XMLSchema#string

Laura Kovanda

http://www.w3.org/2001/XMLSchema#string

Luis Ostrosky-Zeichner

http://www.w3.org/2001/XMLSchema#string

Marc Engelhardt

http://www.w3.org/2001/XMLSchema#string

Misun Lee

http://www.w3.org/2001/XMLSchema#string

Nkechi Azie

http://www.w3.org/2001/XMLSchema#string

Oliver A Cornely

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients

Endemic mycoses: a treatment update

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.

Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain.

Activity of posaconazole in the treatment of central nervous system fungal infections.

Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis.

CNS pharmacokinetics of antifungal agents.

Voriconazole use for endemic fungal infections.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P304

356-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIW305

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27169478

http://www.w3.org/2001/XMLSchema#string

P921

P932

4946023

http://www.w3.org/2001/XMLSchema#string